ArticlePediatric research2026
Genetic variants of ACTC1 gene promoter in pediatric patients with sporadic patent ductus arteriosus and pathological significance.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatent ductus arteriosus (PDA) is a common congenital heart disease. While the ACTC1 gene is crucial for heart development, the role of its promoter variants in PDA pathogenesis remains unclear.
methodsPeripheral blood DNA from 745 subjects (427 PDA patients and 318 healthy controls) was sequenced. Functional assessments included transcriptional activity assays in mouse cardiomyocytes, electrophoretic mobility shift assays (EMSA), and JASPAR database analysis.
resultsEight variants in the ACTC1 promoter region were identified. Four of these, including a novel heterozygous variant, were found exclusively in PDA patients. These variants significantly altered ACTC1 promoter transcriptional activity (p<0.05). Furthermore, EMSA and JASPAR analyses indicated that these variants affect ACTC1 transcription by destroying or generating transcription factor binding sites.
conclusionThis study provides the first evidence associating ACTC1 promoter variants with PDA occurrence, offering novel perspectives on the pathogenesis and potential therapeutic strategies for PDA. IMPACT: DNA from 745 human subjects was sequenced for ACTC1 gene promoter region variants with four variants found only in PDA patients and one was novel. EMSA and dual luciferase reporter experiments found these variants reduced transcriptional activity. Prediction by JASPAR database indicated that these variants alter the transcription factor binding sites. The study, for the first time, confirmed that there are variants at the ACTC1 gene promoter region and these variants cause cellular dysfunction. The variants found in this study suggest the possible pathological role in the formation of PDA.
Identifiers
42120536What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.